NCT07332429
Efficacy and Safety of Alcovit in Reducing Blood Alcohol Concentration
At risk: Primary completion moved at least 7 months later.
See at-risk trials from Galzu Institute of Research, Teaching, Science and Applied Technology
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from May 30, 2026 to Jan 20, 2027 Show 4 more changesShow less
- Start date: May 30, 2026 to Jan 20, 2027
- Eligibility criteria expanded, about 13 words
- Study completion pushed from May 30, 2027 to Jun 30, 2027
- Secondary endpoints: details revised at 1 of 10 entries
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (10)
Show 5 moreShow less
Arms and interventions
Participants receive the investigational device immediately before (2-3 minutes) consuming the standardized alcohol dose.
Participants receive the investigational device immediately after (maximum 5 minutes) consuming the standardized alcohol dose.
Participants receive the placebo immediately before consuming the standardized alcohol dose.
Participants receive the placebo immediately after consuming the standardized alcohol dose.
Devices: Alcovit® (Zeolite Clinoptilolite), Placebo
Sites
1 site in 1 country
- Hospital Santa Casa de Misericórdia de CamposCampos dos Goytacazes, Rio de Janeiro, Brazil